Why the study?
Taiwanese patients are perceived to have a lower incidence of CAT, potentially causing false reassurance, prompting the need for consensus guidance tailored to local practice.
This consensus document provides tailored guidelines for managing cancer-associated thrombosis in Taiwanese patients, addressing local disease burden and the use of NOACs.
Guides NOAC use for cancer-associated thrombosis in Taiwan; extends international guidelines to local incidence and bleeding risks.
Cancer-associated thrombosis (CAT) is a common complication of malignancies. Patients with CAT are at risk of venous thromboembolism recurrence, but also at risk of bleeding while anticoagulated. Taiwanese patients are perceived to have a lower incidence of CAT, likely leading to false reassurance for Taiwanese patients with cancer. Because of this, oncologists and cardiologists from multiple medical institutions in Taiwan have set forth to provide clinical consensus guidelines on the management of CAT, based on local clinical practices and guided by predominant international clinical practice guidelines. This paper aims to describe the current disease burden of cancer-associated venous thromboembolism in Taiwanese cancer patients, and discusses the unmet needs and gaps in the management of this medical complication. It also outlines diagnostic and management strategies relevant to the different treatment options available, such as non-vitamin K antagonist oral anticoagulants.
No takes yet. Share an insight, caveat, or question.
Shao et al. (2023) conducted a review in Cancer-associated thrombosis. Non-vitamin K antagonist oral anticoagulants was evaluated. This consensus paper outlines diagnostic and management strategies for cancer-associated thrombosis in Taiwan, focusing on therapeutic options such as non-vitamin K antagonist oral anticoagulants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: